Which major prize will Sasha Gusev win next in 2024? | Categorical | | | 7 months ago | |
At which conference will Sasha Gusev deliver a keynote presentation in 2024? | Categorical | | | 7 months ago | |
Will Harvard's gene therapy for Diamond-Blackfan Anemia receive FDA approval by end of 2025? | Binary | | | 1 month ago | |
Sasha Gusev to win another major genetics award in 2024? | Binary | | | 7 months ago | |
Will Sasha Gusev publish a breakthrough paper in a top-tier journal by June 1, 2025? | Binary | | | 7 months ago | |
Will 10 major US hospitals adopt CHIEF AI model by end of 2025? | Binary | | | 2 months ago | |
Will CHIEF AI model receive FDA approval by end of 2025? | Binary | | | 2 months ago | |
FDA approval of CHIEF AI model for clinical use by end of 2024? | Binary | | | 2 months ago | |
FDA approval of a new drug based on microRNA discovery by end of 2025? | Binary | | | 3 months ago | |
Institution to announce major collaboration with Ambros or Ruvkun by end of 2025? | Categorical | | | 3 months ago | |
With which institution will Sasha Gusev's lab announce a major collaboration in 2024? | Categorical | | | 7 months ago | |
Will Sasha Gusev's research lab receive a major grant in 2024? | Binary | | | 7 months ago | |
What will be the dominant therapeutic approach for Diamond-Blackfan Anemia by 2026? | Categorical | | | 1 month ago | |
Will Intellia's CRISPR treatment for ATTR enter Phase 2 trials by end of November 2025? | Binary | | | 1 month ago | |
Will Gilead's Livdelzi launch commercially in the US by mid-2025? | Binary | | | 1 month ago | |
What will be the primary outcome of Intellia's CRISPR treatment Phase 1 study for ATTR by end of 2024? | Categorical | | | 1 month ago | |
What will be the outcome of Gilead's Livdelzi Phase 3 study for PBC by end of 2024? | Categorical | | | 1 month ago | |
Which tech company will partner with Harvard for CHIEF AI by end of 2025? | Categorical | | | 2 months ago | |
Which cancer type will CHIEF AI be first used for in trials by end of 2025? | Categorical | | | 2 months ago | |
Will a peer-reviewed study confirm CHIEF AI's accuracy by end of 2025? | Binary | | | 2 months ago | |
Which country will first approve CHIEF AI outside the US by end of 2025? | Categorical | | | 2 months ago | |
First region to implement CHIEF AI in public healthcare by September 2025? | Categorical | | | 2 months ago | |
Adoption of CHIEF AI model by a major US hospital by March 2025? | Binary | | | 2 months ago | |
Independent verification of CHIEF AI model's accuracy by June 2025? | Binary | | | 2 months ago | |
Most effective cancer type for CHIEF AI diagnosis by March 2025? | Categorical | | | 2 months ago | |
Primary concern about CHIEF AI model by end of 2024? | Categorical | | | 2 months ago | |
Victor Ambros or Gary Ruvkun to receive a major science award in 2025? | Binary | | | 3 months ago | |
Journal to publish the most cited paper on microRNA by end of 2025? | Categorical | | | 3 months ago | |
Company to announce first commercial product based on microRNA by end of 2025? | Categorical | | | 3 months ago | |
Significant breakthrough in gene therapy based on microRNA by end of 2025? | Binary | | | 3 months ago | |
Which rare disease category will benefit first from TxGNN's drug repurposing? | Categorical | | | 3 months ago | |
Will TxGNN identify at least one FDA-approved drug repurposed for rare diseases by end of 2024? | Binary | | | 3 months ago | |
Which FDA-approved drug will be the first repurposed by TxGNN for a rare disease? | Categorical | | | 3 months ago | |
Will TxGNN model's findings be featured in another high-impact journal by end of 2024? | Binary | | | 3 months ago | |
Will TxGNN lead to a new clinical trial for a rare disease by mid-2024? | Binary | | | 3 months ago | |
Which institution will primarily collaborate with Kempner Institute on TxGNN by end of 2024? | Categorical | | | 3 months ago | |